Discoveries in Down syndrome: Moving basic science to clinical care

Progress in Brain Research

Volumn 197, Issue , 2012, Pages 199-221

  Kleschevnikov, A M ^a,b   Belichenko, P V ^a,b   Salehi, A ^c,d   Wu, C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Axonal transport; Cognition; Down syndrome; Long term potentiation; Neurogenesis; Synaptic structure

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FLUOXETINE; GAMMA SECRETASE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NOTCH RECEPTOR; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PENTETRAZOLE; PEPTIDES AND PROTEINS; PICROTOXIN; TYROSINE 3 MONOOXYGENASE; VASCULOTROPIN RECEPTOR 1; VESICULAR MONOAMINE TRANSPORTER;

ARTICLE; BRAIN FUNCTION; CALCIUM CELL LEVEL; CHOLINERGIC SYSTEM; CHROMOSOME 16; CHROMOSOME 21; COGNITION; COGNITIVE DEFECT; DOWN SYNDROME; GABAERGIC SYSTEM; GENE EXPRESSION; GENETIC DISORDER; GENETICS; HUMAN; LEARNING; MEMORY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NEUROMODULATION; NONHUMAN; NORADRENERGIC SYSTEM; PHENOTYPE; PRIORITY JOURNAL; TRISOMY 21;

EID: 84860325458     PISSN: 00796123     EISSN: 18757855     Source Type: Book Series    
DOI: 10.1016/B978-0-444-54299-1.00010-8     Document Type: Chapter

References (137)

1. Anderson J.J., Holtz G., Baskin P.P., Turner M., Rowe B., Wang B., et al. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochemical Pharmacology 2005, 69:689-698.
2. Arbuzova S., Hutchin T., Cuckle H. Mitochondrial dysfunction and Down's syndrome. Bioessays 2002, 24:681-684.
3. Barlow G.M., Micales B., Lyons G.E., Korenberg J.R. Down syndrome cell adhesion molecule is conserved in mouse and highly expressed in the adult mouse brain. Cytogenetics and Cell Genetics 2001, 94:155-162.
4. Belichenko N.P., Belichenko P.V., Kleschevnikov A.M., Salehi A., Reeves R.H., Mobley W.C. The "Down syndrome critical region" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome. The Journal of Neuroscience 2009, 29:5938-5948.
5. Belichenko P.V., Kleschevnikov A.M. Deficiency of adult neurogenesis in the Ts65Dn mouse model of Down syndrome. Genetics and etiology of Down syndrome 2011, 177-192. InTech, ISBN 978-953-307-631-7. http://www.intechopen.com/articles/show/title/deficiency-of-adult-neurogenesis-in-the-ts65dn-mouse-model-of-down-syndrome, S. Dey (Ed.).
6. Belichenko P.V., Kleschevnikov A.M., Masliah E., Wu C., Takimoto-Kimura R., Salehi A., et al. Excitatory-inhibitory relationship in the fascia dentata in the Ts65Dn mouse model of Down syndrome. The Journal of Comparative Neurology 2009, 512:453-466.
7. Belichenko P.V., Kleschevnikov A.M., Salehi A., Epstein C.J., Mobley W.C. Synaptic and cognitive abnormalities in mouse models of Down syndrome: Exploring genotype-phenotype relationships. The Journal of Comparative Neurology 2007, 504:329-345.
8. Belichenko P.V., Masliah E., Kleschevnikov A.M., Villar A.J., Epstein C.J., Salehi A., et al. Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. The Journal of Comparative Neurology 2004, 480:281-298.
9. Best T.K., Siarey R.J., Galdzicki Z. Ts65Dn, a mouse model of Down syndrome, exhibits increased GABAB-induced potassium current. Journal of Neurophysiology 2007, 97:892-900.
10. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., et al. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. The Journal of Neuroscience 2010, 30:8769-8779.
11. Brown J.H., Johnson M.H., Paterson S.J., Gilmore R., Longhi E., Karmiloff-Smith A. Spatial representation and attention in toddlers with Williams syndrome and Down syndrome. Neuropsychologia 2003, 41:1037-1046.
12. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 2002, 33:677-688.
13. Campbell W.A., Reed M.L., Strahle J., Wolfe M.S., Xia W. Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase. Journal of Neurochemistry 2003, 85:1563-1574.
14. Carlesimo G.A., Marotta L., Vicari S. Long-term memory in mental retardation: Evidence for a specific impairment in subjects with Down's syndrome. Neuropsychologia 1997, 35:71-79.
15. Cataldo A.M., Petanceska S., Peterhoff C.M., Terio N.B., Epstein C.J., Villar A., et al. App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. The Journal of Neuroscience 2003, 23:6788-6792.
16. Cataldo A.M., Petanceska S., Terio N.B., Peterhoff C.M., Durham R., Mercken M., et al. Abeta localization in abnormal endosomes: Association with earliest Abeta elevations in AD and Down syndrome. Neurobiology of Aging 2004, 25:1263-1272.
17. CDC Improved national prevalence estimates for 18 selected major birth defects-United States, 1999-2001. MMWR. Morbidity and Mortality Weekly Report 2006, 54:1301-1305.
18. Chakrabarti L., Best T.K., Cramer N.P., Carney R.S., Isaac J.T., Galdzicki Z., et al. Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nature Neuroscience 2010, 13:927.
19. Chakrabarti L., Galdzicki Z., Haydar T.F. Defects in embryonic neurogenesis and initial synapse formation in the forebrain of the Ts65Dn mouse model of Down syndrome. The Journal of Neuroscience 2007, 27:11483-11495.
20. Chapman R.S., Hesketh L.J. Behavioral phenotype of individuals with Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews 2000, 6:84-95.
21. Chen-Hwang M.C., Chen H.R., Elzinga M., Hwang Y.W. Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate. Journal of Biological Chemistry 2002, 277:17597-17604.
22. Clark S., Schwalbe J., Stasko M.R., Yarowsky P.J., Costa A.C. Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome. Experimental Neurology 2006, 200:256-261.
23. Colas D., Valletta J.S., Takimoto-Kimura R., Nishino S., Fujiki N., Mobley W.C., et al. Sleep and EEG features in genetic models of Down syndrome. Neurobiology of Disease 2008, 30:1-7.
24. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., et al. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
25. Cooper J.D., Salehi A., Delcroix J.D., Howe C.L., Belichenko P.V., Chua-Couzens J., et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: Reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10439-10444.
26. Cortez M.A., Shen L., Wu Y., Aleem I.S., Trepanier C.H., Sadeghnia H.R., et al. Infantile spasms and Down syndrome: A new animal model. Pediatric Research 2009, 65:499-503.
27. Costa A.C. On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Developmental Neuroscience 2011, 33(5):414-427.
28. Costa A.C., Grybko M.J. Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: A model of Down syndrome. Neuroscience Letters 2005, 382:317-322.
29. Costa A.C., Scott-McKean J.J., Stasko M.R. Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2008, 33:1624-1632.
30. Cramer N.P., Best T.K., Stoffel M., Siarey R.J., Galdzicki Z. GABAB-GIRK2-mediated signaling in Down syndrome. Advances in Pharmacology 2010, 58:397-426.
31. da Costa C.A., Ancolio K., Checler F. C-terminal maturation fragments of presenilin 1 and 2 control secretion of APP alpha and A beta by human cells and are degraded by proteasome. Molecular Medicine 1999, 5:160-168.
32. Das I., Reeves R.H. The use of mouse models to understand and improve cognitive deficits in Down syndrome. Disease Models & Mechanisms 2011, 4(5):596-606.
33. Davisson M.T., Schmidt C., Reeves R.H., Irving N.G., Akeson E.C., Harris B.S., et al. Segmental trisomy as a mouse model for Down syndrome. Progress in Clinical and Biological Research 1993, 384:117-133.
34. Delcroix J.D., Valletta J.S., Wu C., Hunt S.J., Kowal A.S., Mobley W.C. NGF signaling in sensory neurons: Evidence that early endosomes carry NGF retrograde signals. Neuron 2003, 39:69-84.
35. Dierssen M., Arque G., McDonald J., Andreu N., Martinez-Cue C., Florez J., et al. Behavioral characterization of a mouse model overexpressing DSCR1/RCAN1. PLoS One 2011, 6:e17010.
36. Dierssen M., de Lagran M.M. DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): A gene with dosage effect during development and neurogenesis. The Scientific World Journal 2006, 6:1911-1922.
37. Dierssen M., Fillat C., Crnic L., Arbones M., Florez J., Estivill X. Murine models for Down syndrome. Physiology and Behavior 2001, 73:859-871.
38. Edgin J.O., Mason G.M., Allman M.J., Capone G.T., Deleon I., Maslen C., et al. Development and validation of the Arizona Cognitive Test Battery for Down syndrome. Journal of Neurodevelopmental Disorders 2010, 2:149-164.
39. Epstein C.J. The consequences of chromosome imbalance. American Journal of Medical Genetics. Supplement 1990, 7:31-37.
40. Evin G., Barakat A., Masters C.L. BACE: Therapeutic target and potential biomarker for Alzheimer's disease. The International Journal of Biochemistry & Cell Biology 2010, 42:1923-1926.
41. Faizi M., Bader P.L., Tun C., Encarnacion A., Kleschevnikov A., Belichenko P., et al. Comprehensive behavioral phenotyping of Ts65Dn mouse model of down syndrome: Activation of beta(1)-adrenergic receptor by xamoterol as a potential cognitive enhancer. Neurobiology of Disease 2011, 43(2):397-413.
42. Fernandez F., Morishita W., Zuniga E., Nguyen J., Blank M., Malenka R.C., et al. Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nature Neuroscience 2007, 10:411-413.
43. Galdzicki Z., Siarey R.J. Understanding mental retardation in Down's syndrome using trisomy 16 mouse models. Genes, Brain, and Behavior 2003, 2:167-178.
44. Gardiner K., Fortna A., Bechtel L., Davisson M.T. Mouse models of Down syndrome: How useful can they be? Comparison of the gene content of human chromosome 21 with orthologous mouse genomic regions. Gene 2003, 318:137-147.
45. Gardiner K., Herault Y., Lott I.T., Antonarakis S.E., Reeves R.H., Dierssen M. Down syndrome: From understanding the neurobiology to therapy. The Journal of Neuroscience 2010, 30:14943-14945.
46. Gardiner K.J. Molecular basis of pharmacotherapies for cognition in Down syndrome. Trends in Pharmacological Sciences 2010, 31:66-73.
47. German D.C., Manaye K.F., White C.L., Woodward D.J., McIntire D.D., Smith W.K., et al. Disease-specific patterns of locus coeruleus cell loss. Annals of Neurology 1992, 32:667-676.
48. Guardia-Laguarta C., Pera M., Lleo A. gamma-Secretase as a therapeutic target in Alzheimer's disease. Current Drug Targets 2010, 11:506-517.
49. Haapasalo A., Kovacs D.M. The many substrates of presenilin/gamma-secretase. Journal of Alzheimer's Disease 2011, 25:3-28.
50. Haass C., Hung A.Y., Schlossmacher M.G., Oltersdorf T., Teplow D.B., Selkoe D.J. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Annals of the New York Academy of Sciences 1993, 695:109-116.
51. Harashima C., Jacobowitz D.M., Witta J., Borke R.C., Best T.K., Siarey R.J., et al. Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: A model of Down syndrome. The Journal of Comparative Neurology 2006, 494:815-833.
52. Hare J. Trafficking of amyloid beta-precursor protein products C83 and C99 on the endocytic pathway. Biochemical and Biophysical Research Communications 2010, 401:219-224.
53. Heller J.H., Spiridigliozzi G.A., Doraiswamy P.M., Sullivan J.A., Crissman B.G., Kishnani P.S. Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial. American Journal of Medical Genetics Part A 2004, 130A:325-326.
54. Heller J.H., Spiridigliozzi G.A., Sullivan J.A., Doraiswamy P.M., Krishnan R.R., Kishnani P.S. Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24-week open trial. American Journal of Medical Genetics Part A 2003, 116A:111-116.
55. Heneka M.T., Nadrigny F., Regen T., Martinez-Hernandez A., Dumitrescu-Ozimek L., Terwel D., et al. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:6058-6063.
56. Hook E.B. Down syndrome rates and relaxed selection at older maternal ages. American Journal of Human Genetics 1983, 35:1307-1313.
57. Hook E.B., Cross P.K. Paternal age and Down's syndrome genotypes diagnosed prenatally: No association in New York state data. Human Genetics 1982, 62:167-174.
58. Insausti A.M., Megias M., Crespo D., Cruz-Orive L.M., Dierssen M., Vallina I.F., et al. Hippocampal volume and neuronal number in Ts65Dn mice: A murine model of Down syndrome. Neuroscience Letters 1998, 253:175-178.
59. Jin L.W., Shie F.S., Maezawa I., Vincent I., Bird T. Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. American Journal of Pathology 2004, 164:975-985.
60. Khoshnood B., Greenlees R., Loane M., Dolk H. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Birth Defects Research. Part A, Clinical, and Molecular Teratology 2011, 91(Suppl. 1):S16-S22.
61. Kidd P.M. Neurodegeneration from mitochondrial insufficiency: Nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Alternative Medicine Review 2005, 10:268-293.
62. Kim D.Y., Ingano L.A., Carey B.W., Pettingell W.H., Kovacs D.M. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. Journal of Biological Chemistry 2005, 280:23251-23261.
63. Kleschevnikov A.M., Belichenko P.V., Gall J., George L., Nosheny R., Maloney M.T., et al. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease 2012, 45(2):683-691.
64. Kleschevnikov A.M., Belichenko P.V., Villar A.J., Epstein C.J., Malenka R.C., Mobley W.C. Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. The Journal of Neuroscience 2004, 24:8153-8160.
65. Kleschevnikov A.M., Van Volkinburg J., Zhan K., Mobley W.C. Expression of GIRK2 and related proteins after chronic administrations of Prozac in Ts65Dn mice, a genetic model of Down syndrome 2005, Society for Neuroscience, Washington, DC, Program No. 115.7. Abstract Viewer/Itinerary Planner.
66. Kobayashi T., Washiyama K., Ikeda K. Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs. Neuropsychopharmacology 2004, 29:1841-1851.
67. Koehl M., Abrous D.N. A new chapter in the field of memory: Adult hippocampal neurogenesis. European Journal of Neuroscience 2011, 33:1101-1114.
68. Kondoh T., Kanno A., Itoh H., Nakashima M., Honda R., Kojima M., et al. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: A 24-week randomized, double-blind, placebo-controlled trial. International Journal of Psychiatry in Medicine 2011, 41:71-89.
69. Kounnas M.Z., Danks A.M., Cheng S., Tyree C., Ackerman E., Zhang X., et al. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010, 67:769-780.
70. Lai F., Williams R.S. A prospective study of Alzheimer disease in Down syndrome. Archives of Neurology 1989, 46:849-853.
71. Laifenfeld D., Patzek L.J., McPhie D.L., Chen Y., Levites Y., Cataldo A.M., et al. Rab5 mediates an amyloid precursor protein signaling pathway that leads to apoptosis. The Journal of Neuroscience 2007, 27:7141-7153.
72. LeBlanc A.C., Gambetti P. Production of Alzheimer 4kDa beta-amyloid peptide requires the C-terminal cytosolic domain of the amyloid precursor protein. Biochemical and Biophysical Research Communications 1994, 204:1371-1380.
73. Lee H.J., Jung K.M., Huang Y.Z., Bennett L.B., Lee J.S., Mei L., et al. Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4. Journal of Biological Chemistry 2002, 277:6318-6323.
74. Lejeune J., Gautier M., Turpin R. Study of somatic chromosomes from 9 mongoloid children. Comptes Rendus Hebdomadaires des Séances de l'Académie des Sciences 1959, 248:1721-1722.
75. Li Y.M. Gamma-secretase: A catalyst of Alzheimer disease and signal transduction. Molecular Interventions 2001, 1:198-207.
76. Liu C., Belichenko P.V., Zhang L., Fu D., Kleschevnikov A.M., Baldini A., et al. Mouse models for Down syndrome-associated developmental cognitive disabilities. Developmental Neuroscience 2011, 33(5):404-413.
77. Llorens-Martin M.V., Rueda N., Tejeda G.S., Florez J., Trejo J.L., Martinez-Cue C. Effects of voluntary physical exercise on adult hippocampal neurogenesis and behavior of Ts65Dn mice, a model of Down syndrome. Neuroscience 2010, 171:1228-1240.
78. Lockrow J., Boger H., Bimonte-Nelson H., Granholm A.C. Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behavioural Brain Research 2011, 221:610-622.
79. Lorenzi H.A., Reeves R.H. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Brain Research 2006, 1104:153-159.
80. Lott I.T., Osann K., Doran E., Nelson L. Down syndrome and Alzheimer disease: Response to donepezil. Archives of Neurology 2002, 59:1133-1136.
81. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience 2000, 20:9104-9110.
82. Mann D.M., Yates P.O., Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathology and Applied Neurobiology 1984, 10:185-207.
83. Mann D.M., Yates P.O., Marcyniuk B., Ravindra C.R. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathology and Applied Neurobiology 1986, 12:447-457.
84. Marin-Padilla M. Pyramidal cell abnormalities in the motor cortex of a child with Down's syndrome. A Golgi study. The Journal of Comparative Neurology 1976, 167:63-81.
85. McGeer E.G., Norman M., Boyes B., O'Kusky J., Suzuki J., McGeer P.L. Acetylcholine and aromatic amine systems in postmortem brain of an infant with Down's syndrome. Experimental Neurology 1985, 87:557-570.
86. Murchison C.F., Zhang X.Y., Zhang W.P., Ouyang M., Lee A., Thomas S.A. A distinct role for norepinephrine in memory retrieval. Cell 2004, 117:131-143.
87. Nixon R.A. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases. Neurobiology of Aging 2005, 26:373-382.
88. O'Bryan J.P., Mohney R.P., Oldham C.E. Mitogenesis and endocytosis: What's at the INTERSECTIoN?. Oncogene 2001, 20:6300-6308.
89. Owen D.J., Collins B.M. Vesicle transport: A new player in APP trafficking. Current Biology 2010, 20:R413-R415.
90. Pallardo F.V., Lloret A., Lebel M., d'Ischia M., Cogger V.C., Le Couteur D.G., et al. Mitochondrial dysfunction in some oxidative stress-related genetic diseases: Ataxia-Telangiectasia, Down syndrome, Fanconi Anaemia and Werner syndrome. Biogerontology 2010, 11:401-419.
91. Parker S.E., Mai C.T., Canfield M.A., Rickard R., Wang Y., Meyer R.E., et al. Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Research. Part A, Clinical and Molecular Teratology 2010, 88:1008-1016.
92. Pasternak S.H., Bagshaw R.D., Guiral M., Zhang S., Ackerley C.A., Pak B.J., et al. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. Journal of Biological Chemistry 2003, 278:26687-26694.
93. Pennington B.F., Moon J., Edgin J., Stedron J., Nadel L. The neuropsychology of Down syndrome: Evidence for hippocampal dysfunction. Child Development 2003, 74:75-93.
94. Perez-Cremades D., Hernandez S., Blasco-Ibanez J.M., Crespo C., Nacher J., Varea E. Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. Journal of Neural Transmission 2010, 117:445-455.
95. Popov V.I., Kleschevnikov A.M., Klimenko O.A., Stewart M.G., Belichenko P.V. Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. The Journal of Comparative Neurology 2011, 519:1338-1354.
96. Prasher V.P., Adams C., Holder R. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: Open label study. International Journal of Geriatric Psychiatry 2003, 18:549-551.
97. Prasher V.P., Farrer M.J., Kessling A.M., Fisher E.M., West R.J., Barber P.C., et al. Molecular mapping of Alzheimer-type dementia in Down's syndrome. Annals of Neurology 1998, 43:380-383.
98. Qin W., Ho L., Pompl P.N., Peng Y., Zhao Z., Xiang Z., et al. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. Journal of Biological Chemistry 2003, 278:50970-50977.
99. Rissman R.A., Mobley W.C. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. Journal of Neurochemistry 2011, 117:613-622.
100. Roth D., Cuatrecasas P. The distributed partnering model for drug discovery and development 2010, Ewing Marion Kauffman Foundation, January 26, 2010, 9pp.
101. Rueda N., Florez J., Martinez-Cue C. Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neuroscience Letters 2008, 433:22-27.
102. Rueda N., Llorens-Martin M., Florez J., Valdizan E., Banerjee P., Trejo J.L., et al. Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. Journal of Alzheimer's Disease 2010, 21:277-290.
103. Sabo S.L., Lanier L.M., Ikin A.F., Khorkova O., Sahasrabudhe S., Greengard P., et al. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. Journal of Biological Chemistry 1999, 274:7952-7957.
104. Salehi A., Delcroix J.D., Belichenko P.V., Zhan K., Wu C., Valletta J.S., et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 2006, 51:29-42.
105. Salehi A., Faizi M., Belichenko P.V., Mobley W.C. Using mouse models to explore genotype-phenotype relationship in Down syndrome. Mental Retardation and Developmental Disabilities Research Reviews 2007, 13:207-214.
106. Salehi A., Faizi M., Colas D., Valletta J.S., Laguna J., Takimoto-Kimura R., et al. Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome. Science Translational Medicine 2009, 1:7-17.
107. Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. Journal of Neural Transmission 2006, 113:1625-1644.
108. Schmid S.L., McNiven M.A., De Camilli P. Dynamin and its partners: A progress report. Current Opinion in Cell Biology 1998, 10:504-512.
109. Schuchmann S., Muller W., Heinemann U. Altered Ca2+ signaling and mitochondrial deficiencies in hippocampal neurons of trisomy 16 mice: A model of Down's syndrome. The Journal of Neuroscience 1998, 18:7216-7231.
110. Selkoe D., Kopan R. Notch and presenilin: Regulated intramembrane proteolysis links development and degeneration. Annual Review of Neuroscience 2003, 26:565-597.
111. Selkoe D.J., Yamazaki T., Citron M., Podlisny M.B., Koo E.H., Teplow D.B., et al. The role of APP processing and trafficking pathways in the formation of amyloid beta-protein. Annals of the New York Academy of Sciences 1996, 777:57-64.
112. Shinohara M., Sato N., Kurinami H., Takeuchi D., Takeda S., Shimamura M., et al. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. Journal of Biological Chemistry 2010, 285:22091-22102.
113. Shizuka-Ikeda M., Matsubara E., Ikeda M., Kanai M., Tomidokoro Y., Ikeda Y., et al. Generation of amyloid beta protein from a presenilin-1 and betaAPP complex. Biochemical and Biophysical Research Communications 2002, 292:571-578.
114. Siarey R.J., Stoll J., Rapoport S.I., Galdzicki Z. Altered long-term potentiation in the young and old Ts65Dn mouse, a model for Down syndrome. Neuropharmacology 1997, 36:1549-1554.
115. Slepnev V.I., De Camilli P. Accessory factors in clathrin-dependent synaptic vesicle endocytosis. Nature Reviews. Neuroscience 2000, 1:161-172.
116. Sofroniew M.V., Howe C.L., Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annual Review of Neuroscience 2001, 24:1217-1281.
117. Spiridigliozzi G.A., Heller J.H., Crissman B.G., Sullivan-Saarela J.A., Eells R., Dawson D., et al. Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series. American Journal of Medical Genetics. Part A 2007, 143A:1408-1413.
118. Stamnes M. Regulating the actin cytoskeleton during vesicular transport. Current Opinion in Cell Biology 2002, 14:428-433.
119. Sung N.S., Crowley W.F., Genel M., Salber P., Sandy L., Sherwood L.M., et al. Central challenges facing the national clinical research enterprise. JAMA: The Journal of the American Medical Association 2003, 289:1278-1287.
120. Tang B.L. Neuronal protein trafficking associated with Alzheimer disease: From APP and BACE1 to glutamate receptors. Cell Adhesion & Migration 2009, 3:118-128.
121. Tralau-Stewart C.J., Wyatt C.A., Kleyn D.E., Ayad A. Drug discovery: New models for industry-academic partnerships. Drug Discovery Today 2009, 14:95-101.
122. Trazzi S., Mitrugno V.M., Valli E., Fuchs C., Rizzi S., Guidi S., et al. APP-dependent up-regulation of Ptch1 underlies proliferation impairment of neural precursors in Down syndrome. Human Molecular Genetics 2011, 20:1560-1573.
123. Van Nostrand W.E., Schmaier A.H., Wagner S.L. Potential role of protease nexin-2/amyloid beta-protein precursor as a cerebral anticoagulant. Annals of the New York Academy of Sciences 1992, 674:243-252.
124. Van Nostrand W.E., Wagner S.L., Shankle W.R., Farrow J.S., Dick M., Rozemuller J.M., et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:2551-2555.
125. Vetrivel K.S., Barman A., Chen Y., Nguyen P.D., Wagner S.L., Prabhakar R., et al. Loss of cleavage at {beta}'-site contributes to apparent increase in {beta}-amyloid peptide (A{beta}) secretion by {beta}-secretase (BACE1)-glycosylphosphatidylinositol (GPI) processing of amyloid precursor protein. Journal of Biological Chemistry 2011, 286:26166-26177.
126. Vetrivel K.S., Cheng H., Lin W., Sakurai T., Li T., Nukina N., et al. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. Journal of Biological Chemistry 2004, 279:44945-44954.
127. Wisniewski K.E., Laure-Kamionowska M., Wisniewski H.M. Evidence of arrest of neurogenesis and synaptogenesis in brains of patients with Down's syndrome. The New England Journal of Medicine 1984, 311:1187-1188.
128. Wisniewski K.E., Wisniewski H.M., Wen G.Y. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Annals of Neurology 1985, 17:278-282.
129. Wolfe M.S. Gamma-secretase inhibition and modulation for Alzheimer's disease. Current Alzheimer Research 2008, 5:158-164.
130. Wu C., Cui B., He L., Chen L., Mobley W.C. The coming of age of axonal neurotrophin signaling endosomes. Journal of Proteomics 2009, 72:46-55.
131. Wu C., Ramirez A., Cui B., Ding J., Delcroix J.D., Valletta J.S., et al. A functional dynein-microtubule network is required for NGF signaling through the Rap1/MAPK pathway. Traffic 2007, 8:1503-1520.
132. Xia W. From presenilinase to gamma-secretase, cleave to capacitate. Current Alzheimer Research 2008, 5:172-178.
133. Yagishita S., Morishima-Kawashima M., Tanimura Y., Ishiura S., Ihara Y. DAPT-induced intracellular accumulations of longer amyloid beta-proteins: Further implications for the mechanism of intramembrane cleavage by gamma-secretase. Biochemistry 2006, 45:3952-3960.
134. Yu T., Li Z., Jia Z., Clapcote S.J., Liu C., Li S., et al. A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions. Human Molecular Genetics 2010, 19:2780-2791.
135. Yu T., Liu C., Belichenko P., Clapcote S.J., Li S., Pao A., et al. Effects of individual segmental trisomies of human chromosome 21 syntenic regions on hippocampal long-term potentiation and cognitive behaviors in mice. Brain Research 2010, 1366:162-171.
136. Zhang L., Fu D., Belichenko P.V., Liu C., Kleschevnikov A.M., Pao A., et al. Genetic analysis of Down syndrome facilitated by mouse chromosome engineering. Bioengineered Bugs 2012, 45(2):683-691. (in press).
137. Zhang M., Haapasalo A., Kim D.Y., Ingano L.A., Pettingell W.H., Kovacs D.M. Presenilin/gamma-secretase activity regulates protein clearance from the endocytic recycling compartment. The FASEB Journal 2006, 20:1176-1178.